Abcam and Molecular Devices announce strategic collaboration

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

First CatchPoint®SimpleStep®ELISA kits launching at SLAS 2018, Feb 3-7, San Diego, USA

Cambridge, UK, San Jose, CA, USA, February 5, 2018: Abcam, a global innovator in life science reagents and tools, and Molecular Devices, LLC, a leading provider of high-performance bioanalytical measurement solutions for the life science industry, today announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers. 

The initial collaboration combines proprietary technologies from both organisations to create high sensitivity fluorescent ELISA kits, which are immunoassays used to quantify target proteins in basic research, high throughput screening and diagnostics. The immunoassay market is estimated to reach over $25bn by 2019 due to increased use in cancer, infectious diseases and the introduction of novel biomarkers1

John Baker, SVP Portfolio and Business Development said: “Collaborating with other leading organisations like Molecular Devices allows us to combine the latest technologies and rapidly provide researchers with innovative tools that will help accelerate their work. We are excited to be launching the first of our combined kits at SLAS2018 and are looking forward to creating further tools that will bring measurable benefit to the industry.”

Scott Greenstone, Director of Open Innovation and Reagents at Molecular Devices, commented: “We are thrilled to offer our customers this new combination of our proven CatchPoint fluorescence technology with Abcam’s high-quality antibodies and ELISA expertise. Optimized for our industry-leading plate readers, these kits will provide customers with a cohesive solution that enables better results faster. We believe this collaborative approach to new product development is a winning combination for customers and we will be working together throughout 2018 to further expand the offering.”  

With an industry demand for fast, easy-to-use and sensitive ELISAs, the new CatchPoint SimpleStep ELISA kits combine the simplicity and speed of Abcam’s SimpleStep ELISA protocol, with its assay time of 90 minutes or less, with Molecular Devices’ fluorescent CatchPoint technology to facilitate enhanced protein detection for researchers seeking a fast, reproducible, high-sensitivity solution that has been validated on the leading fluorometric instruments.

The kits will be for research use only, and available via the Abcam website,

http://www.abcam.com/kits/catchpoint-simplestep-elisa-kits

References

  1. Markets and Markets. 2016. Immunoassay Market – Global Forecast to 2019.

Contacts:

Abcam

Francesca Axe
T: +44 1223 696000

Media enquiries

Dr. Lynne Trowbridge / Tim Watson, Instinctif Partners
T: +44 20 7866 7861
E: abcam@instinctif.com

About Abcam

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results. 

Abcam’s eleven locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software, assay kits and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

To find out more, please visit www.moleculardevices.com